Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
US5674749A · kind A · utility
3Cited by
0References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 26, 1996 |
| Grant date | Oct 7, 1997 |
| Priority date | — |
| Expiry date | Mar 26, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule Melan-A, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of Melan-A and immunogenic compositions containing the molecules, and an adjuvant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.